Literature DB >> 28088074

Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.

Kim C Aalders1, Konstantinos Tryfonidis2, Elżbieta Senkus3, Fatima Cardoso4.   

Abstract

Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Bevacizumab; Breast cancer; Ramucirumab; Sorafenib; Sunitinib; VEGF

Mesh：

Substances：

Year:  2017        PMID： 28088074     DOI： 10.1016/j.ctrv.2016.12.009

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  43 in total

1.  Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.

Authors:  Ionela Sevilla Bujor; Andreea Cioca; Raluca Amalia Ceaușu; Fulga Veaceslav; Cristian Nica; Anca Maria Cîmpean; Marius Raica
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 2.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

3.  RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Authors:  José Baselga; Claudio Zamagni; Patricia Gómez; Begoña Bermejo; Shigenori E Nagai; Bohuslav Melichar; Arlene Chan; Lászlo Mángel; Jonas Bergh; Frederico Costa; Henry L Gómez; William J Gradishar; Clifford A Hudis; Bernardo L Rapoport; Henri Roché; Patricia Maeda; Liping Huang; Gerold Meinhardt; Joshua Zhang; Lee S Schwartzberg
Journal:  Clin Breast Cancer       Date:  2017-05-22       Impact factor: 3.225

Review 4.  A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach.

Authors:  Andy Wai Kan Yeung; Mohamed M Abdel-Daim; Abdelrahman Ibrahim Abushouk; Kazuaki Kadonosono
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-02       Impact factor: 3.000

Review 5.  The emerging roles of macrophages in cancer metastasis and response to chemotherapy.

Authors:  Luis Rivera Sanchez; Lucia Borriello; David Entenberg; John S Condeelis; Maja H Oktay; George S Karagiannis
Journal:  J Leukoc Biol       Date:  2019-02-05       Impact factor: 4.962

Review 6.  Molecular perspective on targeted therapy in breast cancer: a review of current status.

Authors:  Busra Demir Cetinkaya; Cigir Biray Avci
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 7.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

8.  Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis.

Authors:  Jennifer Xiao; Habib Rahbar; Daniel S Hippe; Mara H Rendi; Elizabeth U Parker; Neal Shekar; Michael Hirano; Kevin J Cheung; Savannah C Partridge
Journal:  NPJ Breast Cancer       Date:  2021-04-16

9.  The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.

Authors:  Fernando Alegre; Amanda R Ormonde; Dayn R Godinez; Anuradha Illendula; John H Bushweller; Luke A Wittenburg
Journal:  Vet Comp Oncol       Date:  2019-08-22       Impact factor: 2.613

10.  Heterotypic Tumor Spheroids in Agitation-Based Cultures: A Scaffold-Free Cell Model That Sustains Long-Term Survival of Endothelial Cells.

Authors:  Teresa Franchi-Mendes; Nuno Lopes; Catarina Brito
Journal:  Front Bioeng Biotechnol       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.